HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 24, No. 09, September 2020 – 3D Technology: Additive Manufacturing Applications and Prospects       » Results of CD30 CAR-T Cell Therapy Trial Shows Promise for Hodgkin Lymphoma Patients       » Emerging Technologies and Innovations amid a Global Pandemic       » Monitoring COVID-19 Patients with AI-powered Platform       » Singapore Researchers Devise a Rapid COVID-19 Test Kit for the Detection of Neutralising Antibodies (NAbs) Against SARS-CoV-2       » Novel Ventilator Conceptualized by Singapore Clinicians Provides Efficient and Personalized Breathing Support for COVID-19 patients      
Vol 24, No. 08, August 2020   |   Issue PDF view/purchase
BIOBOARD - REST OF THE WORLD
Isolated Antibodies from COVID-19 Patients show Potential for Treatment
Researchers at Columbia University Irving Medical Center identify neutralizing antibodies against SARS-CoV-2 virus from COVID-19 Patients.

The human body’s immune response to an infection involves a myriad of cellular and molecular activities. One of which includes the production of antibodies that bind to the foreign microorganism for destruction by the immune system.

A team of researchers from the Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patient which are among the most potent in neutralising the novel coronavirus. These antibodies have the potential to be produced in large quantities by pharmaceutical companies and provide a new treatment option, especially early in the course of infection.

"We now have a collection of antibodies that's more potent and diverse compared to other antibodies that have been found so far, and they are ready to be developed into treatments," says David Ho, MD, scientific director of the Aaron Diamond AIDS Research Center and professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, who directed the work.

The researchers have confirmed that their purified, strongly neutralizing antibodies provide significant protection from SARS-CoV-2 infection in hamsters, and they are planning further studies in other animals and people. The findings were published in the journal Nature.

SARS-CoV-2 neutralizing antibodies produced by COVID-19 patients could be used to treat other patients or even prevent infection in people exposed to the virus while drugs and vaccines are still under development in clinical trials.

The Columbia team found a more diverse variety of antibodies than previous efforts, including new, unique antibodies that were not reported earlier.

"These findings show which sites on the viral spike are most vulnerable," Dr Ho said. "Using a cocktail of different antibodies that are directed to different sites in spike will help prevent the virus becoming resistant to the treatment."

Elucidating on its broad use, Dr Ho shared that these antibodies could also be useful after a vaccine is available especially if it doesn’t work well in the elderly, the antibodies could help to play a key role in protection against COVID-19.

This research demonstrates that people with severe disease are more likely to have a durable antibody response, however more research needs to be done to answer the critical question about how long immunity to COVID-19 will last.

The team is now planning to further test their strategy in other animal models and eventually move on to humans. If found to be successful these neutralizing antibodies could be given to COVID-19 patients to battle against the virus.

Although tremendously informative for researchers developing vaccines and antiviral therapies, the findings are early-stage preclinical results and the antibodies are not yet ready for use in people.

 

NEWS CRUNCH  
news PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season
news PharmaSources.com to Help Propel the Chinese API Export Business with E-Trade Session CPhI China Top API Exporters & Products
news Singapore Biomedical Company Appointed as a Certified Service Provider by 10x Genomics
news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy